The length of this therapy is dictated by your weight and how fast your body responds to the treatment
In a type 1 diabetic Akita mouse model, which was used as a nonobese insulin-dependent model of spontaneous type 1 diabetes, empagliflozin treatment attenuated diabetes-induced rise in renal expression of markers of kidney growth by reducing the cyclin-dependent kinase inhibitors p27 and p21, which were over-expressed in early diabetic kidneys (152)
"[Anti-arrhythmic effect of phytoadaptogens]." Eksp Klin Farmakol 63 (2000): 29-31
doi:10.1161/JAHA.125.041369
These create inflammation, which causes temporary swelling
[6] Similarly, observational studies using healthcare databases have suggested that patients prescribed GLP-1 agonists for diabetes or obesity appear to have lower rates of alcohol-related hospital admissions and reduced self-reported drinking compared to those on other medications, though these findings are limited by potential confounding factors